Back

Impact of systolic blood pressure on ischemic and bleeding events and the efficacy and safety of rivaroxaban monotherapy: a post-hoc analysis of the AFIRE trial

30 August 2025 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Hypertension pharmacotherapy updates Anticoagulants ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Shinichi Yamanaka

Tohoku University Hospital, Sendai (Japan)

3 More presentations in this session

Presentation thumbnail
Genetic inhibition of angiopoietin-like protein 3, 4, and 8 on cardiovascular disease risk
Professor X. Hua (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Efficacy and harms associated with polypills for primary and secondary prevention of cardiovascular disease: a systematic review and meta-analysis.
Professor A. Hernandez (Storrs, US)
Abstract Slides Video
Presentation thumbnail
Community pharmacist intervention to enhance adherence in patients initiating cardiovascular medication: the PHARM-ADHERE randomized controlled trial
Miss A. Watteyne (Ghent, BE)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertension pharmacotherapy updates

The Event

Event poster

ESC Congress 2025

30 August 2025 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Impact of baseline C-reactive protein on the efficacy and safety of rivaroxaban monotherapy in atrial fibrillation and stable coronary artery disease: a post-hoc AFIRE analysis
thumbnail
Congress Session
Integrated management of atrial fibrillation: addressing comorbidities, risk factors, and lifestyle
thumbnail
Congress Session
Key takeaways from ESC Congress 2025 together with World Congress of Cardiology (2)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources